Show simple item record

dc.contributor.authorde Bono, JSen_US
dc.contributor.authorSmith, MRen_US
dc.contributor.authorSaad, Fen_US
dc.contributor.authorRathkopf, DEen_US
dc.contributor.authorMulders, PFen_US
dc.contributor.authorSmall, EJen_US
dc.contributor.authorShore, NDen_US
dc.contributor.authorFizazi, Ken_US
dc.contributor.authorDe Porre, Pen_US
dc.contributor.authorKheoh, Ten_US
dc.contributor.authorLi, Jen_US
dc.contributor.authorTodd, MBen_US
dc.contributor.authorRyan, CJen_US
dc.contributor.authorFlaig, TWen_US
dc.date.accessioned2016-09-05T13:16:48Z
dc.date.issued2016-07-08en_US
dc.identifier.citationEuropean urology, 2016en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/98
dc.identifier.eissn1873-7560en_US
dc.identifier.doi10.1016/j.eururo.2016.06.033en_US
dc.description.abstractTreatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival and overall survival (OS) when compared to placebo plus prednisone (P).This post hoc analysis investigated clinical responses to docetaxel as first subsequent therapy (FST) among patients who progressed following protocol-specified treatment with AA, and characterized subsequent treatment patterns among older (≥75 yr) and younger (<75 yr) patient subgroups.Data were collected at the final OS analysis (96% of expected death events). Subsequent therapy data were prospectively collected, while response and discontinuation data were collected retrospectively following discontinuation of the study drug.At the discretion of the investigator, 67% (365/546) of patients from the AA arm received subsequent treatment with one or more agents approved for mCRPC.Efficacy analysis was performed for patients for whom baseline and at least one post-baseline prostate-specific antigen (PSA) values were available.Baseline and at least one post-baseline PSA values were available for 100 AA patients who received docetaxel as FST. While acknowledging the limitations of post hoc analyses, 40% (40/100) of these patients had an unconfirmed ≥50% PSA decline with first subsequent docetaxel therapy, and 27% (27/100) had a confirmed ≥50% PSA decline. The median docetaxel treatment duration among these 100 patients was 4.2 mo. Docetaxel was the most common FST among older and younger patients from each treatment arm. However, 43% (79/185) of older patients who progressed on AA received no subsequent therapy for mCRPC, compared with 17% (60/361) of younger patients.Patients with mCRPC who progress with AA treatment may still derive benefit from subsequent docetaxel therapy. These data support further assessment of treatment patterns following AA treatment for mCRPC, particularly among older patients.ClinicalTrials.gov NCT00887198.Treatment patterns for advanced prostate cancer have changed substantially in the last few years. This additional analysis provides evidence of clinical benefit for subsequent chemotherapy in men with advanced prostate cancer whose disease progressed after treatment with abiraterone acetate. Older patients were less likely to be treated with subsequent therapy.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleSubsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-06-21en_US
rioxxterms.versionofrecord10.1016/j.eururo.2016.06.033en_US
rioxxterms.licenseref.startdate2016-07-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean urologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.embargo.termsNot knownen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record